ClinicalTrials.gg
Active, not recruitingNCT04884035Updated Jul 20, 2026

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

A Phase 1 interventional study of CC-220 and Rituximab in Lymphoma, B-Cell, sponsored by Celgene. Active, not recruiting at 36 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
224
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing vincristine in Lymphoma, B-Cell — 1 open to participants now, 3 under way, 1 of them phase 3. Vincristine · Lymphoma, B-Cell.

Planned enrollment
4th of 14
224 · median 62
Started
2021
with 1 other
Phase 1
Only one
of the 14
Registered
13th of 14
by date
Lead sponsor
1 of 14
Celgene

Among the 14 studies testing vincristine in Lymphoma, B-Cell, this one is the 4th largest by planned enrollment, is one of 2 that started in 2021, is the only one in phase 1, and was the 13th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

1 of the 14 studies testing vincristine in Lymphoma, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vincristine

Vincristine: first FDA approval 1963 (ONCOVIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing vincristine in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and/or CC-99282 and R-CHOP-21 combination has been defined.

03

Conditions studied

  • Lymphoma, B-Cell

Browse trials for

Keywords

  • Iberdomide
  • CC-220
  • CC-99282
  • Phase 1
  • B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must satisfy the following criteria to be enrolled in the study:

    1. Is ≥ 18 years of age at the time of signing the form (ICF).
    2. Participant has confirmed (per local evaluation) diagnosis of de novo, previously untreated, a-BCL according to 2016 WHO classification.
    3. Participant has International Prognostic Index (IPI) score 0-5 in Part 1 and IPI 2-5 in Part 2. For the CELMoD and polatuzumab-R-CHP cohort, the subject must also have IPI score 0 to 5 in Part 2A and IPI 2 to 5 in Part 2B.
    4. Participants must have defined by at least one FDG-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).
    5. Participant has an (ECOG) performance status of 0, 1, or 2.
    6. Participants must have the following laboratory values:

      1. (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without growth factor support for 7 days (14 days if peg-G-CSF)
      2. (Hb) ≥ 8 g/dL
      3. (PLT) ≥ 75 x 109/L or ≥ 50 x 109/L in case of documented bone marrow involvement (>50% or tumor cells), without transfusion for 7 days
      4. / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamate pyruvic transaminase (ALT/SGPT) ≤ 2.5 x (ULN). In the case of documented liver involvement by lymphoma, ALT/SGPT and AST/SGOT must be ≤ 5.0 x ULN.
      5. Serum total ≤ 2.0 mg/dL except in cases of Gilbert's syndrome, then ≤ 5.0 mg/dl. Subjects receiving polatuzumab vedotin must have serum total bilirubin \< 1.5 × ULN (26 μmol/L) (corresponding to mild degree as per National Cancer Institute Organ Dysfunction Working Group [NCI ODWG] criteria) except in cases of Gilbert's syndrome, then ≤ 3.0 mg/dl (51 μmol/L).
      6. Estimated serum (CrCl) of ≥ 50 mL/min using the modification of diet in renal disease () formula.
    7. All participants must:

      1. Have an understanding that the study drug could have a potential teratogenic risk.
      2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 or CC-99282 Pregnancy Prevention Plan for Participants in Clinical trials.
    8. Females of (FCBP) must:

      a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy.

    9. Male participants must:

      1. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.

Exclusion criteria

Exclusion Criteria:

  • The presence of any of the following will exclude a participant from enrollment:

    1. Any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
    2. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.
    3. Any other subtype of lymphoma.
    4. Documented or suspected CNS involvement by lymphoma.
    5. Persistent diarrhea or malabsorption ≥ Grade 2 ( v5.0), despite medical management.
    6. Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).
    7. Subjects with a history of progressive multifocal leukoencephalopathy.
    8. Chronic systemic therapy or
    9. Impaired cardiac function or cardiac disease, including any of the following:

      a. (LVEF) \< 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)

    10. Major surgery ≤ 2 weeks prior to starting CC-220 or CC-99282; participant must have recovered from any clinically significant effects of recent surgery.
    11. Any condition causing inability to swallow tablets.
    12. Known seropositivity for or active viral infection with (HIV)
    13. Known chronic active (hepatitis B virus surface antigen [HBsAg] positive and/or hepatitis B core antibody [anti-HBc] positive with viral DNA positive) or C (positive serology requiring treatment and/or with evidence of liver damage) infection
    14. History of other , unless being free of the disease for ≥ 3 years; exceptions to the ≥ 3-year time limit include history of the following:

      1. Localized nonmelanoma skin cancer
      2. Carcinoma in situ of the cervix
      3. Carcinoma in situ of the breast
      4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node [TNM] staging system) or prostate cancer that has been treated with curative intent.
    15. to the active substance or to murine proteins, or to any of the other of rituximab or polatuzumab vedotin.
    16. Known hypersensitivity to any component of CHOP/CHP regimen.
    17. Known allergy to thalidomide, pomalidomide, or lenalidomide.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (estimated)

Study arms

  • Experimental
    Administration of CC-220 with R-CHOP-21

    CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment

    Drug: CC-220 · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

  • Experimental
    Administration of CC-99282 with R-CHOP-21

    CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: CC-99282

  • Experimental
    Administration of CC-220 with polatuzumab-R-CHP

    CC-220 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment

    Drug: CC-220 · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: Polatuzumab vedotin · Drug: Rituximab

  • Experimental
    Administration of CC-99282 with polatuzumab-R-CHP

    CC-99282 to be administered orally in combination with Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (polatuzumab-R-CHP) for 6 cycles of treatment

    Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Prednisone · Drug: CC-99282 · Drug: Polatuzumab vedotin · Drug: Rituximab

Interventions

  • DrugCC-220

    CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

    Also known as: Iberdomide, BMS-986382

  • Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles

  • Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles

  • Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles

  • Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles

  • Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles

    Also known as: Prednisolone

  • CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.

    Also known as: BMS-986369

  • Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

  • Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) - Part 1

    Frequency of dose-limiting toxicities (DLT) associated with addition of iberdomide (CC-220) to R-CHOP-21 therapy and the addition of CC-99282 to R-CHOP-21 therapy

    Time frame: During the first 2 cycles of treatment (each cycle is 21 days)

  2. Recommended Phase 2 Dose (RP2D) - Part 1

    Defined as the dose that will be selected for dose expansion based on MTD

    Time frame: During the first cycle of treatment (each cycle is 21 days)

  3. Safety and tolerability of CC-220 and CC-99282 at RP2D - Part 2

    AEs evaluated using NCI CTCAE criteria, v. 5.0, including treatment -emergent adverse events (TEAEs) and laboratory assessments

    Time frame: From the first dose of any IP until 28 days after the last dose of IP

  4. Maximum Tolerated Dose (MTD) - Part 2A

    Frequency of DLTs associated with addition of iberdomide (CC-220) to polatuzumab-R-CHP therapy and the addition of CC-99282 to polatuzumab-R-CHP therapy

    Time frame: During the first cycle of treatment (each cycle is 21 days)

  5. Recommended Phase 2 Dose (RP2D) - Part 2A

    Defined as the dose that will be selected for dose expansion based on MTD

    Time frame: During the first cycle of treatment (each cycle is 21 days)

Secondary outcomes

  1. Best overall response rate (ORR)

    The proportion of participants with best overall response achieved during the study as either Complete Response or Partial Response before subsequent anti-lymphoma therapy

    Time frame: Up to 4 years

  2. Complete Metabolic Response Rate (CMRR)

    The proportion of participants experiencing complete metabolic response (CMR) before receiving any subsequent anti-lymphoma therapy

    Time frame: Up to 4 years

  3. Time to Response (TTR)

    The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the date of first documented response (≥ PR)

    Time frame: Up to 4 years

  4. Duration of Response (DOR)

    The time from the earliest date of documented response (≥ PR) to the first occurrence of relapse or progression

    Time frame: Up to 4 years

  5. Progression-free Survival (PFS)

    The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the first occurrence of disease progression or death from any cause

    Time frame: Up to 4 years

  6. Overall Survival (OS)

    The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to death from any cause

    Time frame: Up to 4 years

  7. Pharmacokinetics - Cmax for CC-220

    Maximum plasma concentration of drug

    Time frame: At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days)

  8. Pharmacokinetics - Ctrough for CC-220

    Minimum or trough concentration

    Time frame: At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days

  9. Pharmacokinetics - Tmax for CC-220

    Time to maximum plasma concentration

    Time frame: At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days

  10. Pharmacokinetics - Cmax for CC-99282

    Maximum plasma concentration

    Time frame: At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days

  11. Pharmacokinetics - Ctrough for CC-99282

    Minimum or trough concentration

    Time frame: At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days

  12. Pharmacokinetics - Tmax for CC-99282

    Time to maximum plasma concentration

    Time frame: At Cycle 1 Day 7, Cycle 1 Day 15, and Cycle 2 Day 7 (each cycle is 21 days

07

Study locations

36 sites
  • Local Institution - 162
    Birmingham, Alabama 35233, United States
  • Local Institution - 154
    Scottsdale, Arizona 85259, United States
  • Local Institution - 169
    Duarte, California 91010, United States
  • Local Institution - 160
    Jacksonville, Florida 32224, United States
  • Local Institution - 161
    Marietta, Georgia 30060, United States
  • Local Institution - 159
    Kansas City, Kansas 66160, United States
  • Local Institution - 166
    Wichita, Kansas 67214, United States
  • Local Institution - 152
    Rochester, Minnesota 55905-0001, United States
  • Local Institution - 163
    Saint Louis Park, Minnesota 55426, United States
  • Local Institution - 151
    Omaha, Nebraska 68198, United States
  • Local Institution - 170
    Charlotte, North Carolina 28204, United States
  • Local Institution - 164
    Winston-Salem, North Carolina 27157, United States
  • Local Institution - 155
    Houston, Texas 77003, United States
  • Local Institution - 168
    Murray, Utah 84107, United States
  • Local Institution - 171
    St. George, Utah 84790, United States
  • Local Institution - 501
    Adelaide, South Australia 5000, Australia
  • Local Institution - 503
    Perth, WA 6000, Australia
  • Local Institution - 702
    Athens, 10676, Greece
  • Local Institution - 704
    Athens, 11 527, Greece
  • Local Institution - 701
    Athens, 12464, Greece
  • Local Institution - 700
    Thessaloniki, 57010, Greece
  • Local Institution - 605
    Skórzewo, Greater Poland Voivodeship 60-185, Poland
  • Local Institution - 601
    Gdansk, 80-952, Poland
  • Local Institution - 600
    Krakow, 30-727, Poland
  • Local Institution - 603
    Słomniki, 32-090, Poland
  • Local Institution - 602
    Warsaw, 02-781, Poland
  • Local Institution - 604
    Wroclaw, 50-367, Poland
  • Local Institution - 300
    Seoul, 06351, South Korea
  • Local Institution - 302
    Seoul, 138-736, South Korea
  • Local Institution - 301
    Seoul, 3080, South Korea
  • Local Institution - 201
    Barcelona, 08916, Spain
  • Local Institution - 203
    Málaga, 29010, Spain
  • Local Institution - 200
    Salamanca, 37007, Spain
  • Local Institution - 403
    Taichung, 40447, Taiwan
  • Local Institution - 402
    Taichung, 407, Taiwan
  • Local Institution - 400
    Taipei, 100229, Taiwan
08

References and documents

Publications

  • Wu C, Meyer A, Tun AM. Diffuse Large B-Cell Lymphoma Presenting in a Background of Rosai-Dorfman Disease. Case Rep Hematol. 2026 May 17;2026:6560267. doi: 10.1155/crh/6560267. eCollection 2026. PubMed 42158929 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2028, 86 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 86 months is above that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 12, 2021
StartActual
Sep 15, 2021
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04884035
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
May 12, 2021
Start date
Sep 15, 2021
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jul 20, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Iberdomide · Vincristine · Golcadomide · Polatuzumab vedotin

Start the discussion